- 专利标题: Anti-c-Met antibody having HGF activity and use thereof
-
申请号: US14123533申请日: 2012-06-04
-
公开(公告)号: US09631020B2公开(公告)日: 2017-04-25
- 发明人: Young Woo Park , Ki Won Jo , Chan Woong Park , Seok Ho Yoo , Myeoung Hee Jang , Hye Nan Kim , Seon Ha Yun , Kyu Won Cho , Mi Ra Park
- 申请人: Young Woo Park , Ki Won Jo , Chan Woong Park , Seok Ho Yoo , Myeoung Hee Jang , Hye Nan Kim , Seon Ha Yun , Kyu Won Cho , Mi Ra Park
- 申请人地址: KR Daejeon KR Daejeon
- 专利权人: Korea Research Institute of Bioscience and Biotechnology,Y-Biologics Inc.
- 当前专利权人: Korea Research Institute of Bioscience and Biotechnology,Y-Biologics Inc.
- 当前专利权人地址: KR Daejeon KR Daejeon
- 优先权: KR10-2011-0054177 20110603
- 国际申请: PCT/KR2012/004395 WO 20120604
- 国际公布: WO2012/165925 WO 20121206
- 主分类号: C07K16/28
- IPC分类号: C07K16/28 ; A61K39/00
摘要:
Disclosed are a human antibody comprising a human complementarity-determining region (CDR), which binds specifically to c-Met, and a framework region (FR), a polynucleotide encoding the human antibody, an expression vector comprising the polynucleotide, a transformant transformed with the expression vector, a method of producing the human antibody B7 by culturing the transformant, a wound healing composition comprising the human antibody as an active ingredient, a cell regeneration composition comprising the antibody as an active ingredient, and a drug conjugate comprising a drug linked to the human antibody. The c-Met-specific human antibody can function as an HGF mimic that can be used as a wound healing composition. The antibody can be widely used to determine the treatment and prognosis of various diseases, including neuronal infarction, progressive nephropathy, liver cirrhosis, lung fibrosis, kidney injury, liver injury, lung injury, and ulcerative wounds, which are treated by activation of HGF or c-Met.
公开/授权文献
- US20140193431A1 ANTI-C-MET ANTIBODY HAVING HGF ACTIVITY AND USE THEREOF 公开/授权日:2014-07-10
信息查询